For the Inventor, By the Inventor

Enter assignee name

Cupertino, CA, United States of America

Durect Corporation

USPTO Granted Patents = 93

CIPO Patents = 10

EPO Patents = 25

Trademarks = 14

Forward Citations = 2,565

Loading Chart...

Loading Chart...

103 inventors (with patents filed for the assignee):

Su Il Yum (29 out of 91 patents)

John W Gibson (25 out of 36 patents)

Arthur J Tipton (18 out of 43 patents)

4. Felix T Theeuwes (17 out of 261 patents)

5. Roger Fu (15 out of 15 patents)

6. Michael S Zamloot (15 out of 22 patents)

7. Huey-Ching Su (14 out of 15 patents)

8. John Middleton (13 out of 25 patents)

9. Grant Schoenhard (12 out of 13 patents)

10. Guohua Chen (11 out of 42 patents)

11. Wendy Chao (9 out of 10 patents)

12. WeiQi Lin (7 out of 7 patents)

13. James E Brown (7 out of 12 patents)

14. Michael H Arenberg (7 out of 8 patents)

15. Keith Edward Branham (7 out of 12 patents)

Core Competencies:

Sustained Release Drug Delivery

Oxygenated Cholesterol Sulfates

Pharmaceutically Active Agent Complexes

Depot Formulations

Oral Pharmaceutical Dosage Forms

Transdermal Delivery Systems

Controlled Delivery System

Injectable Controlled Release Composition

Short Duration Depot Formulations

Rheological Modifiers

High Viscosity Liquid Carriers

Zero-Order Prolonged Release Implants

93 patents: Sort by Forward Citations

1. 12433877 - Sustained release drug delivery systems and related methods (2025-10-07),

2. 12226423 - Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide (2025-02-18),

3. 11771624 - Sustained release drug delivery systems with reduced impurities and related methods (2023-10-03),

4. 11612609 - Uses of oxygenated cholesterol sulfates (OCS) (2023-03-28),

5. 11529420 - Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same (2022-12-20),

6. 11406646 - Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide (2022-08-09),

7. 11400019 - Sustained release drug delivery systems with reduced impurities and related methods (2022-08-02),

8. 11285217 - Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material (2022-03-29),

9. 11179326 - Short duration depot formulations (2021-11-23),

10. 11083796 - Peroxide removal from drug delivery vehicle (2021-08-10),

11. 10786517 - Uses of oxygenated cholesterol sulfates (OCS) (2020-09-29),

12. 10758623 - Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same (2020-09-01),

13. 10682340 - Depot formulations (2020-06-16),

14. 10668011 - Depot formulations (2020-06-02),

15. 10603312 - Transoral dosage forms comprising sufentanil (2020-03-31),

Durect Corporation is a biopharmaceutical company that develops innovative products for the treatment of chronic diseases. Their solutions are focused on developing drug delivery technology platforms and therapeutics in areas such as pain management, metabolic diseases, and oncology. With a strong commitment to research and development, Durect Corporation aims to improve patients' lives by providing effective and convenient treatment options.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

93 Patents

#7 in Cupertino, CA

#928 in California

#3,887 in US

#8,039 in the World

Cupertino, CA, United States of America

Durect Corporation

Forward Citations = 2,565

103 inventors:

Su Il Yum (29 out of 91 patents)

John W Gibson (25 out of 36 patents)

Arthur J Tipton (18 out of 43 patents)

4. Felix T Theeuwes (17 out of 261 patents)

5. Roger Fu (15 out of 15 patents)

Please report any incorrect information to support@idiyas.com

Loading…